Page 51 - 2020_11-Haematologica-web

Pediatric acute lymphoblastic leukemia
Cancer. 2018;65(7):e27062.
136. Brown P, Pieters R, Biondi A. How I treat
infant leukemia. Blood. 2019;133(3):205-
214.
137. Inaba H, Pui CH. Immunotherapy in pedi-
atric acute lymphoblastic leukemia. Cancer
Metastasis Rev. 2019;38(4):595-610.
138. Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N
Engl J Med. 2017;376(9):836-847.
139. Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lym- phoblastic leukemia. Blood. 2018;131(14):
1522-1531.
140.Brown PA, Ji L, Xu X, et al. A randomized
phase 3 trial of blinatumomab versus chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior effica-
cy and tolerability of blinatumomab: a report from Children's Oncology Group Study AALL1331. Blood. 2019;134(Suppl 2):LBA-1.
141. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740-753.
142.Bhojwani D, Sposto R, Shah NN, et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lym- phoblastic leukemia. Leukemia. 2019;33 (4):884-892.
143. Jabbour E, Ravandi F, Kebriaei P, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4(2):230-234.
144.Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.
N Engl J Med. 2018;378(5):439-448.
145. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remis- sions in leukemia. N Engl J Med.
2014;371(16):1507-1517.
146. Shah NN, Fry TJ. Mechanisms of resistance
to CAR T cell therapy. Nat Rev Clin Oncol.
2019;16(6):372-385.
147.Gardner RA, Ceppi F, Rivers J, et al.
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenua- tion of antileukemic efficacy. Blood. 2019;134(24):2149-2158.
148. Zhang X, Lu XA, Yang J, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4(10):2325-2338.
149. Frismantas V, Dobay MP, Rinaldi A, et al. Ex vivo drug response profiling detects recur- rent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017;129(11):e26-e37.
haematologica | 2020; 105(11)
2539